Kiniksa Pharmaceuticals International, plc
KNSA
$76.75
-$1.08-1.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 25.43M | 22.59M | 14.20M | 18.44M | 17.83M |
| Total Depreciation and Amortization | 472.00K | 468.00K | 467.00K | 384.00K | 358.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.42M | 16.82M | 13.35M | 15.88M | 11.57M |
| Change in Net Operating Assets | 5.87M | 10.32M | 25.88M | -1.02M | -1.67M |
| Cash from Operations | 47.20M | 50.20M | 53.89M | 33.68M | 28.09M |
| Capital Expenditure | -663.00K | -161.00K | -633.00K | -671.00K | -165.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -72.92M | -31.76M | -70.18M | -62.08M | -3.72M |
| Cash from Investing | -73.58M | -31.92M | -70.81M | -62.76M | -3.88M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 17.58M | 6.39M | 8.58M | 16.25M | 12.75M |
| Repurchase of Common Stock | -5.47M | -316.00K | -918.00K | -4.35M | -2.05M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 12.11M | 6.07M | 7.66M | 11.90M | 10.70M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.28M | 24.36M | -9.26M | -17.18M | 34.91M |